CR11481A - Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos - Google Patents

Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos

Info

Publication number
CR11481A
CR11481A CR11481A CR11481A CR11481A CR 11481 A CR11481 A CR 11481A CR 11481 A CR11481 A CR 11481A CR 11481 A CR11481 A CR 11481A CR 11481 A CR11481 A CR 11481A
Authority
CR
Costa Rica
Prior art keywords
therapeutic applications
antagonist
same
hedgehog
route
Prior art date
Application number
CR11481A
Other languages
English (en)
Inventor
John Thomas Rusell
La Pericot Mohr Gal
Minetto Giacomo
Cornelia Bakker Annette
Ferruzzi Pietro
Original Assignee
Siena Biotech Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siena Biotech Spa filed Critical Siena Biotech Spa
Publication of CR11481A publication Critical patent/CR11481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos heterociclicos que modulan la via de senalizacion de hedgehog, su composicion farmaceutica y sus aplicaciones terapeuticas
CR11481A 2007-12-13 2010-06-08 Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos CR11481A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07024218 2007-12-13

Publications (1)

Publication Number Publication Date
CR11481A true CR11481A (es) 2010-10-15

Family

ID=39432963

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11481A CR11481A (es) 2007-12-13 2010-06-08 Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos

Country Status (16)

Country Link
US (1) US8592463B2 (es)
EP (1) EP2227456A2 (es)
JP (1) JP5620821B2 (es)
CN (1) CN101896472A (es)
AR (1) AR069652A1 (es)
AU (1) AU2008335880B2 (es)
BR (1) BRPI0820856A2 (es)
CA (1) CA2709203A1 (es)
CO (1) CO6210735A2 (es)
CR (1) CR11481A (es)
EA (1) EA017918B1 (es)
IL (1) IL206298A0 (es)
NZ (1) NZ586121A (es)
TW (1) TW200930370A (es)
WO (1) WO2009074300A2 (es)
ZA (1) ZA201004185B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101918420A (zh) * 2007-12-27 2010-12-15 无限药品股份有限公司 癌症治疗方法
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
CN102803246A (zh) * 2009-06-11 2012-11-28 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
US9891149B2 (en) 2011-08-08 2018-02-13 Thermo Fisher Scientific Oy Method and apparatus for automated analysis
FI20115785A0 (fi) * 2011-08-08 2011-08-08 Thermo Fisher Scientific Oy Menetelmä ja laite automaattiseen analyysiin
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
KR102240329B1 (ko) 2013-06-07 2021-04-14 더 스크립스 리서치 인스티튜트 섬유증의 소분자 억제제
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016094570A1 (en) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
WO2019062657A1 (zh) * 2017-09-30 2019-04-04 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110016054B (zh) * 2019-03-15 2021-10-22 四川大学 含磷氮苯并杂环结构的离子单体、用其阻燃的共聚酯型离聚物及它们的制备方法和应用
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234318T3 (es) * 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
EP1435947B1 (en) * 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
CN102803246A (zh) * 2009-06-11 2012-11-28 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用

Also Published As

Publication number Publication date
US8592463B2 (en) 2013-11-26
EA017918B1 (ru) 2013-04-30
CA2709203A1 (en) 2009-06-18
EP2227456A2 (en) 2010-09-15
AU2008335880A1 (en) 2009-06-18
AR069652A1 (es) 2010-02-10
WO2009074300A8 (en) 2009-11-19
AU2008335880B2 (en) 2014-03-13
JP2011506366A (ja) 2011-03-03
US20100286114A1 (en) 2010-11-11
IL206298A0 (en) 2010-12-30
WO2009074300A3 (en) 2009-10-01
CO6210735A2 (es) 2010-10-20
WO2009074300A2 (en) 2009-06-18
ZA201004185B (en) 2011-10-26
TW200930370A (en) 2009-07-16
BRPI0820856A2 (pt) 2019-05-14
CN101896472A (zh) 2010-11-24
EA201000784A1 (ru) 2010-12-30
NZ586121A (en) 2012-03-30
JP5620821B2 (ja) 2014-11-05

Similar Documents

Publication Publication Date Title
CR11481A (es) Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos
CL2008003188A1 (es) Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
CL2015003139A1 (es) Variantes de polipéptidos receptores de activina y usos de los mismos.
GT201000376A (es) Compuestos organicos
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
MX393345B (es) Composiciones farmaceuticas de moduladores c-met.
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
GT200900027A (es) Compuestos organicos
ECSP099785A (es) Anticuerpos anti-notch1 nrr y sus métodos de uso
ECSP11011417A (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2007001674A1 (es) Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas.
AR059978A1 (es) Composiciones farmaceuticas
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)